Literature DB >> 10478580

Epidemiological and clinical characteristics of myasthenia gravis in Belgrade, Yugoslavia (1983-1992).

D Lavrnić1, M Jarebinski, V Rakocević-Stojanović, Z Stević, S Lavrnić, S Pavlović, R Trikić, I Tripković, V Nesković, S Apostolski.   

Abstract

This is the first epidemiological study of myasthenia gravis (MG) in the area of Belgrade. During the survey period (1983 1992), 124 incidental cases of MG were observed, producing an average annual incidence rate of 7.1 per million population (women, 8.3; men, 5.8). Age and sex specific incidence rates for females demonstrated a bimodal pattern, with the first peak in the age group between 20 and 40, and the second peak in the age group 70-80. The age-specific rates for males showed unimodal pattern, reaching a maximum in the age group between 60 and 80. There was a tendency of more frequent disease appearance in the urban as opposed to the suburban districts. On the prevalence day, December 31, 1992, the point prevalence rate was 121.5 per million (women, 142.5; men, 98.8). Only for incidental cases, the point prevalence rate was 77.1 (women, 83.2; men, 70.4). The average annual mortality rate was 0.47 per million (females, 0.52; males, 0.42), while cumulative lethality was 5.6 (women, 5.6; men, 5.7). Most frequently initial symptoms were ocular, occurring in 58% patients. Through the period of investigation ocular symptoms were generalized in 68%, most frequently in the first 2 years (62.5%). Thymoma was confirmed in 11.3% of patients. In this group there was equal presence of both sexes, older median age at onset, and more severe clinical course of MG. Associated autoimmune disease was found in 17 out of 124 incidental cases (13.7%). The most common were thyroid diseases (7.3%). Family history of MG was recorded in 2 cases belonging to 1 family (1.6%).

Entities:  

Mesh:

Year:  1999        PMID: 10478580     DOI: 10.1111/j.1600-0404.1999.tb00733.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  8 in total

1.  Nationwide population-based epidemiological study of myasthenia gravis in taiwan.

Authors:  Chien-Hsu Lai; Hung-Fu Tseng
Journal:  Neuroepidemiology       Date:  2010-06-03       Impact factor: 3.282

2.  Efficacy of prednisone for the treatment of ocular myasthenia (EPITOME): A randomized, controlled trial.

Authors:  Michael Benatar; Michael P Mcdermott; Donald B Sanders; Gil I Wolfe; Richard J Barohn; Richard J Nowak; Michael Hehir; Vern Juel; Hans Katzberg; Rabi Tawil
Journal:  Muscle Nerve       Date:  2016-01-27       Impact factor: 3.217

3.  Assessment of health-related quality of life in patients with myasthenia gravis in Belgrade (Serbia).

Authors:  Ivana Z Basta; Tatjana D Pekmezović; Stojan Z Perić; Darija B Kisić-Tepavčević; Vidosava M Rakočević-Stojanović; Zorica D Stević; Dragana V Lavrnić
Journal:  Neurol Sci       Date:  2012-08-09       Impact factor: 3.307

Review 4.  A systematic review of population based epidemiological studies in Myasthenia Gravis.

Authors:  Aisling S Carr; Chris R Cardwell; Peter O McCarron; John McConville
Journal:  BMC Neurol       Date:  2010-06-18       Impact factor: 2.474

5.  Epidemiology of seropositive myasthenia gravis in Greece.

Authors:  K Poulas; E Tsibri; A Kokla; D Papanastasiou; T Tsouloufis; M Marinou; P Tsantili; T Papapetropoulos; S J Tzartos
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-09       Impact factor: 10.154

6.  A population based epidemiological study on myasthenia gravis in Estonia.

Authors:  M Oöpik; A-E Kaasik; J Jakobsen
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-12       Impact factor: 10.154

7.  Global prevalence of myasthenia gravis and the effectiveness of common drugs in its treatment: a systematic review and meta-analysis.

Authors:  Nader Salari; Behnaz Fatahi; Yalda Bartina; Mohsen Kazeminia; Reza Fatahian; Payam Mohammadi; Shamarina Shohaimi; Masoud Mohammadi
Journal:  J Transl Med       Date:  2021-12-20       Impact factor: 5.531

8.  Incidence of thymoma in myasthenia gravis: a systematic review.

Authors:  Zhi-Feng Mao; Xue-An Mo; Chao Qin; Yong-Rong Lai; Maree L Hackett
Journal:  J Clin Neurol       Date:  2012-09-27       Impact factor: 3.077

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.